PAX5
PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.
Overview
Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage. Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes. In turn, regulates cell adhesion and migration, induces V(H)-to-D(H)J(H) recombination, facilitates pre-B-cell receptor signalling and promotes development to the mature B-cell stage.
CIViC holds 5 clinical evidence items and 1 assertion across 2 variants. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.98, animal model 0.27, genetic association 0.45, somatic mutation 0.83). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.
- 1 · What it is
PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage. Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes.
- 3 · How drugs use it
No product in this corpus aims at PAX5 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:8619 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q02548 (protein name, function text, keywords and locations (REST API)); CIViC gene PAX5 (5 evidence items, 1 assertions, 2 variants; diseases: B-lymphoblastic Leukaemia With PAX5 P.P80R, B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000196092 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: melanoma 0.56, acute lymphoblastic leukaemia 0.67, non-Hodgkin lymphoma 0.71, skin cancer 0.57, breast cancer 0.61, lung cancer 0.54 (GraphQL API, CC0)); IntOGen PAX5 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage. Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage-specific genes. In turn, regulates cell adhesion and migration, induces V(H)-to-D(H)J(H) recombination, facilitates pre-B-cell receptor signalling and promotes development to the mature B-cell stage. Repression of the cohesin-release factor WAPL causes global changes of the chromosomal architecture in pro-B cells to facilitate the generation of a diverse antibody repertoire. Also participates in the inhibition of lytic EBV reactivation by modulating viral BZLF1 activity. Location: Nucleus (UniProt). Locus 9p13.2 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.71 with non-Hodgkin lymphoma (MONDO_0018908)
- Leukaemia: Open Targets association 0.69 with leukaemia (MONDO_0005059)
- Breast cancer: Open Targets association 0.61 with breast cancer (MONDO_0007254)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Lung cancer: Open Targets association 0.54 with lung cancer (MONDO_0008903)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 5 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: B-lymphoblastic Leukaemia With PAX5 P.P80R.
Latest papers
topQuery for this target: (TITLE:"PAX5" OR ABSTRACT:"PAX5" OR TITLE:"paired box 5" OR ABSTRACT:"paired box 5" OR TITLE:"Paired box protein Pax-5" OR ABSTRACT:"Paired box protein Pax-5" OR TITLE:"PAX-5" OR ABSTRACT:"PAX-5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PAX5, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTBL1XR1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetTNFRSF14
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetEBF1
Shares Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetRUNX1T1
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetBCL11B
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetCCND3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Breast cancer (all types).
- TargetJAK3
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).